Ellen Koenig

2.2k citations

23 papers · 822 indexed · 1 hit paper · h-index 12

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 14
- HIV Research and Treatment 14
Infectious Diseases 23
- HIV/AIDS drug development and treatment 18
- HIV/AIDS Research and Interventions 10
- Viral Infections and Vectors 2

Co-authors: Edwin DeJesus (7 shared papers)Andrew Cheng (5 shared papers)Erin Quirk (4 shared papers)Joseph M. Custodio (2 shared papers)Kirsten White (4 shared papers)Devi SenGupta (1 shared paper)Marisa Montes (1 shared paper)Anton Pozniak (1 shared paper)
Journals: The Lancet HIV (4 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (3 papers)Journal of the International AIDS Society (3 papers)The Lancet (2 papers)AIDS Research and Human Retroviruses (2 papers)
Partner nations: United States Thailand United Kingdom

In The Last Decade

Ellen Koenig

23 papers receiving 804 citations

Hit Papers

align trajectories log scale

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial 2017 · 278 citations

Peers

Countries citing papers authored by Ellen Koenig

Since Specialization

Citations

This map shows the geographic impact of Ellen Koenig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Koenig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Koenig more than expected).

Fields of papers citing papers by Ellen Koenig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Koenig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Koenig. The network helps show where Ellen Koenig may publish in the future.

Co-authors

The 25 scholars most cited alongside Ellen Koenig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ellen Koenig Line = papers co-authored together Ellen Koenig links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet ·Paul E. Sax, Anton Pozniak, Marisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph M. Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin Quirk Hit paper breakdown →	2017	278
2	Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial The Lancet HIV ·Eric S. Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K. Rockstroh, Jean‐Michel Molina, Ellen Koenig, Ya-Pei Liu, Joseph M. Custodio, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk	2018	117
3	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results The Journal of Infectious Diseases ·Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee, Andrew Cheng	2013	84
4	Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial The Lancet HIV ·Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E Sanchez, Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig	2022	65
5	Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study The Lancet HIV ·Kathleen Squires, Cissy Kityo, Sally Hodder, Margaret Johnson, Evgeny Voronin, Debbie Hagins, Anchalee Avihingsanon, Ellen Koenig, Shuping Jiang, Kirsten White, Andrew Cheng, Javier Szwarcberg, Huyen Cao	2016	62
6	Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial JAIDS Journal of Acquired Immune Deficiency Syndromes ·Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L. Stephens, Edwin DeJesus, Hui Wang, Rima Acosta, Huyen Cao, Erin Quirk, Hal Martin, Tariro Makadzange	2019	44
7	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial The Lancet HIV ·Anchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, Chien‐Ching Hung, Ellen Koenig, Sasisopin Kiertiburanakul, Man‐Po Lee, Khuanchai Supparatpinyo, Fujie Zhang, Sophia Rahman, Michelle L. D’Antoni, Hongyuan Wang, Jason T. Hindman, Hal Martin, Jared M. Baeten, Taisheng Li	2023	32
8	Field Evaluation of the Determine Rapid Human Immunodeficiency Virus Diagnostic Test in Honduras and the Dominican Republic Journal of Clinical Microbiology ·Carol Palmer, José M. Dubón, Ellen Koenig, Eddy Pérez-Then, Arba L. Ager, Dushyantha Jayaweera, Raúl Cuadrado‐Matías, Ada Rivera, Alex Rubido, Dennis A. Palmer	1999	28
9	Screening for active tuberculosis in HIV testing centre The Lancet ·Marcos Espinal, Arthur Reingold, Ellen Koenig, MARIA LAVANDERA, Santa Salas Sánchez	1995	22
10	Brief Report JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Giuliano Rizzardini, Jan Fehr, Hui C. Liu, Michael E. Abram, Huyen Cao, Javier Szwarcberg	2015	17
11	Comparison of Methods to Detect Recent HIV Type 1 Infection in Cross-Sectionally Collected Specimens from a Cohort of Female Sex Workers in the Dominican Republic AIDS Research and Human Retroviruses ·Swati B. Gupta, Gary Murphy, Ellen Koenig, Carlos Adon, Chris Beyrer, David D. Celentano, Sarwar Khawaja, Frangiscos Sifakis, John Parry, Walter L. Straus	2007	14
12	Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition AIDS ·Richard Novák, Barbara Metch, Susan Buchbinder, Robinson Cabello, Yeycy Donastorg, John-Peter Figoroa, Hend Adbul-Jauwad, Patrice Joseph, Ellen Koenig, David S. Metzger, Magda Sobieszycz, Mark Tyndall, Carmen Zorilla	2013	11
13	P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate Journal of the International AIDS Society ·Edwin DeJesus, Paul Sax, Michael T. Yin, Frank Post, Shinichi Oka, Ellen Koenig, Benoît Trottier, Jaime Andrade‐Villanueva, Huyen Cao, Julie Ryu, Marshall W. Fordyce	2015	9
14	P002: Clinical manifestations of Chikungunya virus infection in HIV-infected individuals: experiences during the Dominican Republic's 2014 outbreak Journal of the International AIDS Society ·Robert Paulino, Natalia López Gómez, Paola Lockhart, Ellen Koenig, Adrián Puello	2015	9
15	Distribution of HIV-1 Infection in Different T Lymphocyte Subsets: Antiretroviral Therapy-Naïve vs. Experienced Patients AIDS Research and Human Retroviruses ·Raúl Pérez, Sonia Gibson, Pablo A. López, Ellen Koenig, Marisol De Castro, Yasuhiro Yamamura	2010	5
16	P99 Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate Sexually Transmitted Infections ·Frank A. Post, Paul Sax, Michael S Saag, Michael T. Yin, Shinichi Oka, Ellen Koenig, Benoît Trottier, Jaime Andrade, Huyen Cao, Marshall W. Fordyce	2015	5
17	Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials JAIDS Journal of Acquired Immune Deficiency Syndromes ·Chloe Orkin, Faïza Ajana, Cissy Kityo, Ellen Koenig, Eva Natukunda, Bhumi Gandhi‐Patel, Hui Wang, Yapei Liu, Xuelian Wei, Kirsten White, Tariro Makadzange, Cheryl Pikora, Ian R. McNicholl, Sean E Collins, Diana M. Brainard, Susan K. Chuck	2021	5
18	1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results Open Forum Infectious Diseases ·Onyema Ogbuagu, Sorana Segal‐Maurer, Winai Ratanasuwan, Benoît Trottier, Jason Brunetta, Takuma Shirasaka, Ellen Koenig, Hui Wang, Nicolas Margot, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Jean‐Michel Molina	2022	5
19	Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results Open Forum Infectious Diseases ·Eric S. Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K. Rockstroh, Jean‐Michel Molina, Ellen Koenig, Ya-Pei Liu, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk	2017	4
20	Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. PubMed ·Chloe Orkin, Faïza Ajana, Cissy Kityo, Ellen Koenig, Eva Natukunda, Bhumi Gandhi‐Patel, Hui Wang, Yapei Liu, Xuelian Wei, Kirsten White, Tariro Makadzange, Cheryl Pikora, Ian R. McNicholl, Sean E Collins, Diana M. Brainard, Susan K. Chuck	2021	2

About Ellen Koenig

Ellen Koenig is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Hepatology and Epidemiology, having authored 23 papers that have together received 822 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (10 papers), HIV-related health complications and treatments (5 papers), Hepatitis C virus research (4 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Hepatitis B Virus Studies (2 papers) and Viral Infections and Vectors (2 papers). The work is most often cited by research in Virology (533 citations), Infectious Diseases (760 citations), Emergency Medicine (275 citations), Hepatology (49 citations) and Epidemiology (145 citations). Ellen Koenig has collaborated with scholars based in United States, Thailand and United Kingdom. Frequent co-authors include Edwin DeJesus, Andrew Cheng, Erin Quirk, Joseph M. Custodio, Kirsten White, Devi SenGupta, Marisa Montes, Anton Pozniak, Andrea Antinori and Jacques Reynes. Their work appears in journals such as The Lancet HIV, JAIDS Journal of Acquired Immune Deficiency Syndromes, Journal of the International AIDS Society, The Lancet and AIDS Research and Human Retroviruses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact